# Veterinary CRO and CDMO Market

> Veterinary CRO and CDMO Market Size, Growth Research Report By Application (Drug Development, Toxicology and Safety, Pharmacokinetics and Metabolism, Bioanalysis, Manufacturing), By Service Type (Discovery and Development, Clinical Trial Support, Manufacturing and Packaging, Regulatory Affairs), By Therapeutic Area (Oncology, Cardiovascular, Neurology, Immunology, Infectious Diseases), By Animal Type (Small Animals (Dogs, Cats), Livestock (Cattle, Pigs, Poultry), Aquatic Animals (Fish, Shrimp), Laboratory Animals (Mice, Rats)) - Competitor Industry Analysis and Trends Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.2%
- **2024:** $ 7.34 Billion
- **2025:** $ 7.94 Billion
- **2035:** $ 17.47 Billion
- **Key Players:** Covance (US), Charles River Laboratories (US), Eligo Bioscience (FR), PRA Health Sciences (US), Wuxi AppTec (CN), Kymab (GB), Eurofins Scientific (LU), Medpace (US), Syneos Health (US)

**Report ID:** MRFR/HC/24696-HCR · **Pages:** 128 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/veterinary-cro-and-cdmo-market-26347

---

## Market Summary

## **Global Veterinary CRO and CDMO Market Overview**

As per MRFR analysis, the Veterinary CRO and CDMO Market Size was estimated at 6.82(USD Billion) in 2023. The Veterinary CRO and CDMO Market Industry is expected to grow from 7.34(USD Billion) in 2024 to 13.80(USD Billion) by 2032. The Veterinary CRO and CDMO Market CAGR (growth rate) is expected to be around 8.20% during the forecast period (2024 - 2032).

## **Key Veterinary CRO and CDMO Market Trends Highlighted**

The Veterinary CRO and CDMO market is experiencing ongoing advancements driven by the growing demand for animal health and welfare, particularly in emerging regions. Key market drivers include increased pet ownership, rising disposable income levels, and heightened awareness of animal health. Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) play a vital role in providing specialized services and support to veterinary pharmaceutical companies. Opportunities for growth in this market lie in the expansion of CRO and CDMO capabilities to cater to the growing demand for complex veterinary clinical trials, specialized manufacturing techniques, and regulatory compliance services.

The increasing adoption of advanced technologies such as AI and machine learning in drug development and manufacturing processes is also creating new avenues for innovation and efficiency.Recent trends in the Veterinary CRO and CDMO market include strategic partnerships and acquisitions aimed at expanding service offerings and geographical reach. Additionally, the growing emphasis on personalized medicine and precision diagnostics for animals is opening up avenues for targeted treatments and therapies, further driving market growth.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

## **Veterinary CRO and CDMO Market Drivers**

### **Increasing Demand for Veterinary Pharmaceuticals**

The ever-increasing global population coupled with the growing concern towards animals in terms of health and welfare are arguably some of the key factors that are driving the demand and subsequent growth of the market. In addition to this, the increased prevalence of chronic diseases, including diabetes, cancer, and arthritis among animals, is contributing to the expansion of the market.

Furthermore, the growing popularity of pets and the increased rates of animal ownership, especially for companion animals such as dogs canine and feline, are key factors that are driving the demand for animal drugs, thereby leading to the growth of the Veterinary CRO And CDMO Market Industry.

### Growing Outsourcing Trend in Veterinary Drug Development

One of the major factors that are expected to drive the Veterinary CRO And CDMO Market Industry is the rising outsourcing trend in veterinary drug development. Companies that are engaged in developing veterinary drugs prefer to outsource the tasks to CROs and CDMOs to minimize the costs and focus on their core competencies. CROs and CDMOs offer various services including preclinical and clinical research, regulatory affairs as well as manufacturing.The trend is expected to continue in the future as well because veterinary pharmaceutical companies are always looking for ways to improve their efficiency and reduce their costs.

### **Technological Advancements in Veterinary Drug Development**

Technological advancement in the development of veterinary drugs is one of the critical reasons contributing to the growth of the Veterinary CRO And CDMO Market Industry. The technological advancements include the development of new drug delivery systems such as nanotechnology and gene therapy. These new technologies are helping in the development of more effective and targeted veterinary drugs. Moreover, artificial intelligence and machine learning are helping in speeding up the process of drug development.Thus, technological advancement is expected to have a high impact on driving the veterinary CRO and CDMO market industry in the next few years.

## Veterinary CRO and CDMO Market Segment Insights

### **Veterinary CRO and CDMO Market Application Insights**

The Veterinary CRO And CDMO Market is segmented into Drug Development, Toxicology and Safety, Pharmacokinetics and Metabolism, Bioanalysis, and Manufacturing. Among these segments, Drug Development is expected to hold the largest market share of around 40% in 2024, owing to the rising demand for veterinary drugs and the increasing number of veterinary clinical trials.

The Toxicology and Safety segment is expected to grow at the fastest rate during the forecast period due to the increasing need for safety assessments of veterinary drugs and the growing awareness of animal welfare.The Veterinary CRO And CDMO Market is driven by factors such as the rising prevalence of animal diseases, the increasing demand for companion animals, and the growing awareness of animal health and welfare. The market is expected to be driven by the increasing demand for veterinary drugs and the growing number of veterinary clinical trials.

North America is expected to hold the largest market share in the Veterinary CRO And CDMO Market, followed by Europe and Asia-Pacific. The North American market is driven by the high prevalence of companion animals and the well-developed veterinary healthcare industry.The European market is expected to grow at a steady pace due to the increasing demand for veterinary drugs and the rising awareness of animal welfare. The Asia-Pacific market is expected to witness the fastest growth, owing to the rising prevalence of animal diseases and the increasing demand for companion animals.

Major players in the Veterinary CRO And CDMO Market include Charles River Laboratories International, Inc., Covance Inc., Eurofins Scientific SE, and Merck Co., Inc. These companies offer a wide range of veterinary CRO and CDMO services, including drug development, toxicology and safety, pharmacokinetics and metabolism, bioanalysis, and manufacturing.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Veterinary CRO and CDMO Market Service Type Insights**

The Service Type of the Veterinary CRO And CDMO Market is further divided into Discovery and Development, Clinical Trial Support, Manufacturing and Packaging, and Regulatory Affairs. The Discovery and Development segment was the most popular segment in 2023, and it is expected to lead the market during the forecast period as well, making a varying proportion of the Veterinary CRO And CDMO Market revenue.

The growth of this segment is determined by the demand for innovative veterinary products and the necessity of undertaking an economic and effective drug development process.The Clinical Trial Support segment is also likely to develop rather quickly as it is associated with the increased number of clinical trials and the need for professional support that will allow an increase in the final product’s safety and effectiveness.

The demand for high-quality veterinary products will predispose the popularity of the Manufacturing and Packaging segment of the Veterinary CRO And CDMO Market, as there will also become a high need to develop specialized packaging solutions that will secure the necessary stability of the final drugs.Finally, the importance of the Regulatory Affairs segment can hardly be underestimated as its existence allows to secure compliance with the specific regulatory demands and allows the product’s approval. Due to the fact that more and more regulations appear in the industry, stable growth of the segment is expected.

### **Veterinary CRO and CDMO Market Therapeutic Area Insights**

The Therapeutic Area segment is a crucial aspect of the Veterinary CRO And CDMO Market, with each therapeutic area representing a distinct set of diseases and treatment modalities. Oncology, Cardiovascular, Neurology, Immunology, and Infectious Diseases are among the key therapeutic areas in the veterinary CRO and CDMO market. Oncology, focused on cancer treatment, is a significant therapeutic area due to the rising prevalence of cancer in companion animals.

Veterinary CROs and CDMOs play a vital role in developing and testing novel cancer therapies for animals.The global veterinary oncology market is projected to reach USD 3.24 billion by 2024, growing at a CAGR of 7.5%. Cardiovascular diseases affecting the heart and circulatory system are another major therapeutic area in the veterinary CRO and CDMO market. With the increasing adoption of companion animals, the demand for advanced cardiovascular treatments is growing. The global veterinary cardiovascular market is expected to reach USD 1.96 billion by 2024, exhibiting a CAGR of 6.2%.

Neurology, dealing with disorders of the nervous system, is a specialized therapeutic area in the veterinary CRO and CDMO market.The rising incidence of neurological diseases in animals has led to an increased demand for CRO and CDMO services. 

The global veterinary neurology market is anticipated to reach USD 1.25 billion by 2024, growing at a CAGR of 5.8%. Immunology, focusing on diseases related to the immune system, is a growing therapeutic area in the veterinary CRO and CDMO market. With the increasing understanding of the immune system in animals, there is a growing demand for CRO and CDMO services for developing and testing immunotherapies. The global veterinary immunology market is projected to reach USD 1.12 billion by 2024, growing at a CAGR of 6.0%.

Infectious Diseases, encompassing a wide range of bacterial, viral, and parasitic infections, pose a significant threat to animal health. Veterinary CROs and CDMOs provide critical services in developing and testing vaccines and treatments for infectious diseases. The global veterinary infectious diseases market is expected to reach USD 2.89 billion by 2024, growing at a CAGR of 7.1%. The segmentation of the Therapeutic Area segment provides valuable insights into the specific needs and trends within each therapeutic area, enabling Veterinary CROs and CDMOs to tailor their services and offerings accordingly.

### **Veterinary CRO and CDMO Market Animal Type Insights**

The Animal Type segment is a key driver of growth in the Veterinary CRO And CDMO Market. The growth is attributed to the increasing demand for veterinary services for companion animals, livestock, and aquatic animals. Small animals, such as dogs and cats, accounted for the largest share of the market in 2023, and this trend is expected to continue in the coming years. The growing popularity of pet ownership and increasing awareness of animal welfare are key factors driving the demand for veterinary services for small animals.

Livestock, including cattle, pigs, and poultry, is another significant segment of the Veterinary CRO and CDMO Market.The demand for veterinary services for livestock is driven by the need to improve animal health and productivity, as well as to prevent and control animal diseases. Aquatic animals, such as fish and shrimp, are also a growing segment of the market. The increasing demand for seafood and the need to improve aquaculture practices are driving the growth of this segment. Laboratory animals, such as mice and rats, are used in biomedical research and drug development.

The demand for veterinary services for laboratory animals is expected to remain steady in the coming years.

### **Veterinary CRO and CDMO Market Regional Insights**

The regional segmentation of the Veterinary CRO And CDMO Market offers valuable insights into the market's geographic distribution and growth patterns. North America is expected to dominate the market in 2023, accounting for a significant share of the Veterinary CRO And CDMO Market revenue. The region's large pet population, advanced veterinary infrastructure, and strong research and development capabilities contribute to its dominance.

Europe is another key market, driven by factors such as rising pet ownership rates, increasing awareness of animal health and well-being, and government initiatives to promote animal welfare.The APAC region is anticipated to witness substantial growth in the coming years, attributed to expanding pet ownership, increasing disposable income, and growing awareness of veterinary care. South America and MEA are also expected to contribute to the global market growth, albeit at a slower pace compared to other regions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Veterinary CRO and CDMO Market Key Players And Competitive Insights**

As the Veterinary CRO and CDMO Market moves further into the 21st century, major players in the industry are constantly seeking to gain a competitive edge. Companies are making large investments in research and development, expanding their product portfolios, and the veterinary cro and cdmo market competitive landscape continues to evolve. Much of the current interest and activity within the sector focuses on the veterinary cro and cdmo market, with a number of the leading participants in the industry focusing on the development and introduction of innovative technologies and other solutions.

The overarching factors contributing to this trend include the increasing demand for companion animal health products, the rising incidences of animal diseases, and the increasing awareness of animal welfare. On that note, the veterinary cro and cdmo markets are predicted to be competitive over the next several years.Today, one of the leading companies in the industry is also one of the most comprehensive providers of products and services to the animal health industry. This company focuses heavily on research and development, and in the last year, they made considerable investments in new and improved products and technologies.

They have operations in over 50 countries and serve customers in more than 130 countries around the world. The companies in this space are trusted suppliers of quality products and value to their customers.

A competitor company might have more of a focus on manufacturing, as it would have strong manufacturing capabilities, enabling it to provide high-quality products in bulk and at competitive costs. In fact, the company is known for these capabilities, and it operates with a strong manufacturing presence around the world. The production department has experienced staff members with the knowledge and resources needed to meet the needs of customers around the world while maintaining competent levels of efficiency. The companies have developed a portfolio of well-regarded products, a large collection of prestigious clients, and a formidable reputation.

## **Key Companies in the Veterinary CRO and CDMO Market Include**

## **Veterinary CRO and CDMO Market Industry Developments**

The growth of the market is attributed to the increasing demand for veterinary drugs and biologics, the rising prevalence of animal diseases, and the growing adoption of outsourcing by veterinary pharmaceutical companies.Recent news developments in the Veterinary CRO and CDMO market include: In January 2023, Charles River Laboratories acquired Cognate BioServices, a leading provider of viral vector manufacturing services, for USD 260 million. In March 2023, Thermo Fisher Scientific announced the expansion of its veterinary clinical research services in Europe with the opening of a new facility in Lyon, France.

In May 2023, WuXi AppTec announced a partnership with Bayer to provide integrated drug development and manufacturing services for veterinary products.These developments indicate the growing importance of the Veterinary CRO and CDMO market and the increasing demand for outsourced services by veterinary pharmaceutical companies.

## **Veterinary CRO and CDMO Market Segmentation Insights**

### **Veterinary CRO and CDMO Market Application Outlook**

### **Veterinary CRO and CDMO Market Service Type Outlook**

### **Veterinary CRO and CDMO Market Therapeutic Area Outlook**

### **Veterinary CRO and CDMO Market Animal Type Outlook**

### **Veterinary CRO and CDMO Market Regional Outlook**

## Market Drivers

### Rising Demand for Animal Health Products

The Veterinary CRO and CDMO Market is experiencing a notable increase in demand for animal health products. This surge is driven by a growing awareness of [animal health](https://www.marketresearchfuture.com/reports/animal-health-market-7163) and welfare among pet owners and livestock producers. As consumers become more conscious of the quality of animal care, the need for effective veterinary medicines and vaccines intensifies. According to recent data, the animal health market is projected to reach approximately USD 60 billion by 2025, indicating a robust growth trajectory. This demand compels veterinary contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) to enhance their capabilities in developing innovative solutions tailored to the needs of the veterinary sector.

### Growing Investment in Veterinary Research

Investment in veterinary research is on the rise, significantly impacting the Veterinary CRO and CDMO Market. Increased funding from both public and private sectors is directed towards the development of new veterinary therapeutics and diagnostics. This influx of capital is essential for fostering innovation and supporting the operational capabilities of CROs and CDMOs. Recent reports indicate that venture capital investments in animal health startups have surged, reflecting a strong belief in the potential of veterinary innovations. Consequently, this trend is likely to stimulate further growth in the market, as more resources become available for research and development initiatives.

### Regulatory Support for Veterinary Innovations

The Veterinary CRO and CDMO Market benefits from an evolving regulatory landscape that increasingly supports veterinary innovations. Regulatory bodies are streamlining approval processes for new veterinary drugs and biologics, which encourages investment in research and development. This regulatory facilitation is crucial for CROs and CDMOs, as it allows them to expedite the development timelines of veterinary products. Recent initiatives have been introduced to promote the use of advanced technologies in veterinary medicine, which could potentially lead to a more efficient market. As a result, the collaboration between regulatory agencies and industry stakeholders is likely to foster a more dynamic environment for veterinary product development.

### Technological Integration in Veterinary Research

The integration of advanced technologies in veterinary research is a significant driver for the Veterinary CRO and CDMO Market. Innovations such as artificial intelligence, big data analytics, and genomics are transforming the way veterinary research is conducted. These technologies enable more precise and efficient research methodologies, which can lead to faster product development cycles. For instance, the use of AI in drug discovery has shown promise in identifying potential candidates more rapidly than traditional methods. As the industry embraces these technological advancements, CROs and CDMOs are likely to enhance their service offerings, thereby attracting more clients seeking cutting-edge solutions for veterinary product development.

### Expansion of Veterinary Services in Emerging Markets

The expansion of veterinary services in emerging markets is a crucial driver for the Veterinary CRO and CDMO Market. As economies develop, there is a corresponding increase in the demand for veterinary care and products. This trend is particularly evident in regions where livestock farming is a primary economic activity. The rising middle class in these areas is also contributing to a greater emphasis on pet care, leading to increased spending on veterinary services. Consequently, CROs and CDMOs are presented with opportunities to establish operations in these markets, catering to the growing needs for veterinary research and product development.

## Future Outlook

The Veterinary CRO and CDMO Market is projected to grow at an 8.2% CAGR from 2025 to 2035, driven by increasing pet ownership, advancements in veterinary medicine, and rising demand for animal health products.

**New opportunities:**

- Development of integrated digital platforms for veterinary data management. Expansion of biologics manufacturing capabilities for veterinary applications. Investment in sustainable packaging solutions for veterinary pharmaceuticals.

By 2035, the Veterinary CRO and CDMO Market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Application: Drug Development (Largest) vs. Toxicology and Safety (Fastest-Growing)

In the Veterinary CRO and CDMO Market, the Application segment encompasses various critical areas, notably Drug Development, Toxicology and Safety, Pharmacokinetics and Metabolism, Bioanalysis, and Manufacturing. Among these, Drug Development holds the largest veterinary cro and cdmo market share, driven by the increasing demand for innovative veterinary therapeutics. Toxicology and Safety is emerging as the fastest-growing area, reflecting heightened regulatory scrutiny and a growing emphasis on ensuring animal safety in pharmaceutical development.

Drug Development (Dominant) vs. Toxicology and Safety (Emerging)

Drug Development represents a dominant force in the Veterinary CRO and CDMO Market, characterized by extensive R&D investments aimed at developing novel veterinary drugs and biologics. This sector is driven by the need for safer and more effective treatments for companion and livestock animals. On the other hand, Toxicology and Safety, while currently emerging, is gaining traction due to the increasing regulatory demands for robust safety assessments. Companies in this space are focusing on advanced methodologies to evaluate the safety profiles of veterinary drugs, propelled by innovations in technology and increasing awareness of animal welfare.

### By Service Type: Discovery and Development (Largest) vs. Clinical Trial Support (Fastest-Growing)

In the Veterinary CRO and CDMO Market, the Service Type segment showcases significant diversity, with 'Discovery and Development' emerging as the largest contributor to market share. The segment thrives on the increasing need for innovative solutions in veterinary pharmaceuticals and biologics. In contrast, 'Clinical Trial Support' is gaining traction, reflecting a shift towards specialization in clinical assessments and data management for veterinary studies.

Discovery and Development (Dominant) vs. Clinical Trial Support (Emerging)

The dominance of 'Discovery and Development' in the Veterinary CRO and CDMO Market is attributed to the critical role it plays in the emergence of new animal health products, allowing companies to streamline the R&D process effectively. This segment benefits from robust investments in veterinary research and a high demand for novel therapeutics. 'Clinical Trial Support', on the other hand, has positioned itself as an emerging segment characterized by its tailored offerings for veterinary clinical trials, which are essential for ensuring compliance with regulatory standards and advancing veterinary medicine. Its growth is driven by the increasing complexity of trials and the need for more sophisticated data management solutions.

### By Therapeutic Area: Oncology (Largest) vs. Immunology (Fastest-Growing)

The Veterinary CRO and CDMO Market showcases significant diversity in therapeutic areas, with Oncology dominating the market share. This therapeutic area has garnered attention due to the rising incidence of cancers in pets, leading to an increased demand for specialized research and development services. Following behind, Immunology emerges as a formidable segment, driven by advancements in vaccine development and immune therapies targeting infectious diseases and autoimmune disorders, making it a critical area for future investments.

Oncology (Dominant) vs. Immunology (Emerging)

Oncology represents the dominant therapeutic area within the Veterinary CRO and CDMO Market, characterized by a robust pipeline of drugs and therapies specifically for cancer treatment in animals. This segment benefits from heightened awareness among pet owners regarding cancer, leading to higher investments in research and treatment options. Conversely, Immunology is viewed as an emerging segment, spurred by innovations in immunotherapies and vaccines, especially in response to pandemic-related challenges. Adoption of these therapies is rapidly growing as veterinarians and pet owners alike recognize the importance of preventative medicine and effective management of infectious diseases.

### By Animal Type: Small Animals (Largest) vs. Livestock (Fastest-Growing)

The 'Animal Type' segment in the Veterinary CRO and CDMO Market is characterized by significant market share distribution among various categories. Small animals, particularly dogs and cats, dominate this segment, drawing the majority of investment and resources. Their prevalence in household settings and the increasing awareness of their health needs ensure a steady demand for veterinary services, thus cementing their leadership in market shares.

Small Animals (Dominant) vs. Livestock (Emerging)

The small animals segment remains the dominant force in the Veterinary CRO and CDMO Market, primarily driven by increasing pet ownership and heightened focus on pet wellness. This segment not only benefits from a consistent demand for preventive care and advanced veterinary services but also showcases rising trends in pet pharmaceuticals. Conversely, the livestock segment has emerged as the fastest-growing, fueled by the increasing demand for food sources and innovations in livestock health management. The rise in population and demand for protein-rich diets prompt significant investments and research into livestock health, leading to enhanced veterinary services and products tailored for cattle, pigs, and poultry.

## Regional Market Share Analysis

### North America : Leading Innovation and Research

North America is the largest market for Veterinary CRO and CDMO Market services, holding approximately 45% of the global market share. The region benefits from a robust regulatory framework, significant investment in veterinary research, and a growing demand for animal health products. The increasing prevalence of zoonotic diseases and the rising pet population are key drivers of market growth. Regulatory catalysts, such as streamlined approval processes for veterinary drugs, further enhance market dynamics. The United States is the leading country in this sector, with major players like Covance, Charles River Laboratories, and PRA Health Sciences headquartered there. Canada also plays a significant role, contributing to the competitive landscape. The presence of established companies and a focus on innovation in veterinary medicine position North America as a hub for research and development in the veterinary CRO and CDMO market.

### Europe : Emerging Regulatory Frameworks

Europe is the second-largest market for Veterinary CRO and CDMO Market services, accounting for approximately 30% of the global market share. The region is witnessing growth driven by increasing investments in animal health research and a rising awareness of animal welfare. Regulatory frameworks, such as the European Medicines Agency's guidelines, are evolving to support innovation in veterinary medicine, thereby enhancing market opportunities. The demand for biologics and advanced therapies is also on the rise, further propelling market growth. Leading countries in Europe include Germany, France, and the United Kingdom, where key players like Eligo Bioscience and Eurofins Scientific are making significant contributions. The competitive landscape is characterized by a mix of established firms and emerging biotech companies, fostering innovation. The collaboration between academia and industry is also strengthening the market, positioning Europe as a vital player in the veterinary CRO and CDMO landscape.

### Asia-Pacific : Rapidly Growing Market Potential

Asia-Pacific is rapidly emerging as a significant player in the Veterinary CRO and CDMO Market, holding approximately 20% of the global market share. The region's growth is driven by increasing investments in animal health, rising disposable incomes, and a growing pet population. Countries like China and India are witnessing a surge in demand for veterinary services, supported by favorable government policies and initiatives aimed at improving animal health standards. The region's regulatory environment is also becoming more conducive to innovation, further enhancing market prospects. China is the largest market in the region, with a growing number of domestic and international players entering the market. Companies like Wuxi AppTec are expanding their services to meet the rising demand. The competitive landscape is characterized by a mix of local firms and multinational corporations, fostering a dynamic environment for growth and innovation in veterinary services.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually emerging in the Veterinary CRO and CDMO Market, holding approximately 5% of the global market share. The growth is primarily driven by increasing awareness of animal health, rising investments in veterinary research, and the need for improved livestock management. Regulatory bodies are beginning to establish frameworks to support the development of veterinary products, which is expected to catalyze market growth in the coming years. Countries like South Africa and the UAE are leading the way in veterinary services, with a growing number of local and international players entering the market. The competitive landscape is evolving, with an increasing focus on research and development. The presence of key players and the establishment of partnerships between governments and private sectors are expected to enhance the market's growth trajectory in this region.

## Competitive Benchmarking

The Veterinary CRO and CDMO Market is currently characterized by a dynamic competitive landscape, driven by increasing demand for animal health products and services. Key players are actively engaging in strategies that emphasize innovation, regional expansion, and strategic partnerships. For instance, Covance (US) has positioned itself as a leader in the market by focusing on comprehensive preclinical and clinical services, while Charles River Laboratories (US) continues to enhance its capabilities through technological advancements and acquisitions. These strategies collectively contribute to a competitive environment that is increasingly focused on delivering high-quality, efficient services to meet the evolving needs of the veterinary sector.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of services and innovations, although it also necessitates that companies differentiate themselves through unique offerings and strategic collaborations.
In August Eligo Bioscience (FR) announced a partnership with a leading veterinary pharmaceutical company to develop novel gene-editing therapies for companion animals. This collaboration is significant as it underscores Eligo's commitment to pioneering advanced therapeutic solutions, potentially transforming treatment protocols in veterinary medicine. Such strategic alliances may enhance their market position and foster innovation in the sector.
In September Wuxi AppTec (CN) expanded its global footprint by establishing a new facility in Europe dedicated to veterinary drug development. This move is indicative of Wuxi's strategy to leverage regional expertise and enhance its service offerings, thereby positioning itself as a key player in the European veterinary market. The establishment of this facility may facilitate faster turnaround times and improved access to European clients, aligning with the growing demand for localized services.
In October Syneos Health (US) launched a new digital platform aimed at streamlining clinical trial processes for veterinary products. This initiative reflects a broader trend towards digital transformation within the industry, as companies seek to enhance efficiency and data management capabilities. By adopting such technologies, Syneos Health may improve its competitive edge and respond more effectively to client needs in a rapidly evolving market.
As of October the Veterinary CRO and CDMO Market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, it is likely that competitive differentiation will evolve, shifting from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies position themselves in the market, ultimately enhancing their ability to meet the complex demands of the veterinary sector.

## Recent News & Developments

The growth of the veterinary cro and cdmo market is attributed to the increasing demand for veterinary drugs and biologics, the rising prevalence of animal diseases, and the growing adoption of outsourcing by veterinary pharmaceutical companies.Recent news developments in the Veterinary CRO and CDMO Market include: In January 2023, Charles River Laboratories acquired Cognate BioServices, a leading provider of viral vector manufacturing services, for USD 260 million. In March 2023, Thermo Fisher Scientific announced the expansion of its veterinary clinical research services in Europe with the opening of a new facility in Lyon, France.

In May 2023, WuXi AppTec announced a partnership with Bayer to provide integrated drug development and manufacturing services for veterinary products.These developments indicate the growing importance of the Veterinary CRO and CDMO Market and the increasing demand for outsourced services by veterinary pharmaceutical companies.

## Report Scope

| MARKET SIZE 2024 | 7.34(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 7.942(USD Billion) |
| MARKET SIZE 2035 | 17.47(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.2% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Covance (US), Charles River Laboratories (US), Eligo Bioscience (FR), PRA Health Sciences (US), Wuxi AppTec (CN), Kymab (GB), Eurofins Scientific (LU), Medpace (US), Syneos Health (US) |
| Segments Covered | Application, Service Type, Therapeutic Area, Animal Type |
| Key Market Opportunities | Integration of advanced analytics and artificial intelligence in Veterinary CRO and CDMO Market enhances efficiency and innovation. |
| Key Market Dynamics | Rising demand for innovative veterinary therapeutics drives competition among Contract Research Organizations and Contract Development and Manufacturing Organizations. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Veterinary CRO and CDMO Market by 2035?**
A: The Veterinary CRO and CDMO Market is projected to reach a valuation of 17.47 USD Billion by 2035.

**Q: What was the market valuation of the Veterinary CRO and CDMO Market in 2024?**
A: In 2024, the market valuation of the Veterinary CRO and CDMO Market was 7.34 USD Billion.

**Q: What is the expected CAGR for the Veterinary CRO and CDMO Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Veterinary CRO and CDMO Market during the forecast period 2025 - 2035 is 8.2%.

**Q: Which therapeutic area is projected to have the highest market growth in the Veterinary CRO and CDMO Market?**
A: The Infectious Diseases therapeutic area is projected to grow from 2.67 USD Billion in 2024 to 6.47 USD Billion by 2035.

**Q: What are the key segments of the Veterinary CRO and CDMO Market?**
A: Key segments include Drug Development, Toxicology and Safety, and Manufacturing, among others.

**Q: Which company is a leading player in the Veterinary CRO and CDMO Market?**
A: Covance, based in the US, is recognized as a leading player in the Veterinary CRO and CDMO Market.

**Q: What is the projected growth for the Manufacturing segment in the Veterinary CRO and CDMO Market?**
A: The Manufacturing segment is expected to grow from 1.84 USD Billion in 2024 to 4.27 USD Billion by 2035.

**Q: How does the market for small animals compare to livestock in the Veterinary CRO and CDMO Market?**
A: The market for livestock is projected to grow from 3.0 USD Billion in 2024 to 7.0 USD Billion by 2035, surpassing the small animals segment.

**Q: What services are included in the Clinical Trial Support segment of the Veterinary CRO and CDMO Market?**
A: The Clinical Trial Support segment includes services related to the management and execution of clinical trials for veterinary products.

**Q: What is the anticipated growth for the Bioanalysis segment in the Veterinary CRO and CDMO Market?**
A: The Bioanalysis segment is projected to grow from 1.0 USD Billion in 2024 to 2.4 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/veterinary-cro-and-cdmo-market-26347*